The Clinical Effect of Steroid Therapy on Preserving Residual Hearing after Cochlear Implantation with the Advanced Bionics HiRes Ultra 3D Cochlear Implant System.
cochlear implantation
dexamethasone
hearing implants
partial deafness treatment
prednisone
steroid administration
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
27 Mar 2022
27 Mar 2022
Historique:
received:
27
01
2022
revised:
23
03
2022
accepted:
25
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
(1) Background: The main aim of this study was to assess the clinical effectiveness of two different schemes of administration of steroids ((1) dexamethasone administered intravenously in comparison with (2) combination of steroid treatments: orally administered prednisone and intravenously administered dexamethasone) in comparison with a control group (no steroid administration) on hearing preservation (HP) in patients who underwent an Advanced Bionics cochlear implantation. (2) Methods: Thirty-five adult patients met the inclusion criteria. All patients were randomly divided into three subgroups depending on the scheme of steroid administration: (1) the first subgroup with only intravenously administered dexamethasone (0.1 mg per kg body weight twice a day for three days), (2) the second subgroup with a combination of methods of administration of steroids (intravenous and oral steroid therapy (dexamethasone, 0.1 mg/kg body weight twice a day plus prednisone, 1 mg/kg weight once a day for three days before surgery and after administration of dexamethasone (4th, 5th, 6th day) and after this time the dose of prednisone was reduced)) and (3) the third subgroup without steroid therapy (control group). The results were measured by pure tone audiometry (PTA) in three periods: (1) before implantation, (2) during activation of the processor (one month after implantation), and (3) 12 months after activation. Patients' hearing thresholds before implantation were on average 82 dB HL, 77 dB HL, and 88 dB HL, respectively. (3) Results: The majority of the patients from the first subgroup had hearing preserved partially (77.8%). A similar result was observed in the second study group (oral + i.v.) (partial hearing preservation was found in 61.5% of the participants). The opposite was true in the control group; a plurality of control patients (38.5%) had no measurable hearing 12 months after the activation of the processor. (4) Conclusions: Pharmacological treatment consisting of the administration of steroids in patients who had undergone cochlear implantation with the Advanced Bionics HiRes Ultra 3D cochlear implant system may be beneficial for preserving residual hearing in patients.
Identifiants
pubmed: 35454977
pii: life12040486
doi: 10.3390/life12040486
pmc: PMC9024713
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Pediatr Otorhinolaryngol. 2015 Nov;79(11):1896-900
pubmed: 26384830
J Clin Med. 2021 Jun 28;10(13):
pubmed: 34203443
Cochlear Implants Int. 2018 Jan;19(1):1-13
pubmed: 29073844
Hear Res. 2015 Sep;327:257-64
pubmed: 26117408
Ear Hear. 2020 Jan/Feb;41(1):17-24
pubmed: 31045652
Otolaryngol Clin North Am. 2012 Feb;45(1):155-71
pubmed: 22115688
Otol Neurotol. 2016 Feb;37(2):e135-40
pubmed: 26756147
Audiol Neurootol. 2016;21(3):178-86
pubmed: 27229744
Acta Otolaryngol. 2010 Aug;130(8):888-96
pubmed: 20105110
Med Sci Monit. 2010 Nov;16(11):CR555-62
pubmed: 20980961
Curr Opin Physiol. 2020 Dec;18:49-55
pubmed: 32905432
HNO. 2017 Jan;65(Suppl 1):19-28
pubmed: 27933352
Cochlear Implants Int. 2010 Jun;11 Suppl 1:56-66
pubmed: 21756584
Med Sci Monit. 2018 Apr 22;24:2437-2445
pubmed: 29680860
Life (Basel). 2022 Jan 10;12(1):
pubmed: 35054488